GTCM
JNCE

Gyon Technologies Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Gyon Technologies Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,893
Closed -$188K – 533
2020
Q4 		$188K Buy
+26,893
New +$209K 0.06% 326

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gyon Technologies Capital Management's JNCE Position: Q1 2021 in Review

Gyon Technologies Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 26,893 shares — an estimated $188K sold.

Gyon Technologies Capital Management first reported a position in JNCE in Q4 2020 and held it in 1 quarter. The position peaked at $188K in Q4 2020. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

  • Gyon Technologies Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 26,893 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $188K.
  • Gyon Technologies Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $188K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2021, filed 17 May 2021.